



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Recommendations for the non-pharmacological treatment of apathy in brain disorders

**Citation for published version:**

Manera, V, Abrahams, S, Agüera-Ortiz, L, Bremond, F, Renaud, D, Fairchild, K, Hanon, A, Husain, M, König, A, Lockwood, P, Maribel, P, Radakovic, R, Robert, G, Slachevsky, A, Stella, F, Tribouillard, A, Trimarchi, PD, Verhey, FRJ, Yesavage, J, Zeghari, R & Robert, P 2019, 'Recommendations for the non-pharmacological treatment of apathy in brain disorders', *American Journal of Geriatric Psychiatry*, vol. 28, no. 4, pp. 410-420. <https://doi.org/10.1016/j.jagp.2019.07.014>

**Digital Object Identifier (DOI):**

[10.1016/j.jagp.2019.07.014](https://doi.org/10.1016/j.jagp.2019.07.014)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

American Journal of Geriatric Psychiatry

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# Recommendations for the non-pharmacological treatment of apathy in brain disorders

Manera Valeria<sup>1,2</sup>, Abrahams Sharon<sup>3,4</sup>, Agüera-Ortiz Luis<sup>5</sup>, Bremond François<sup>1,6</sup>, David Renaud<sup>1,7</sup>, Fairchild Kaci<sup>8</sup>, Gros Auriane<sup>1</sup>, Hanon Cécile<sup>9</sup>, Husain Masud<sup>10</sup>, König Alexandra<sup>1,6</sup>, Lockwood Patricia<sup>10</sup>, Pino Maribel<sup>11</sup>, Radakovic Ratko<sup>4,12,13</sup>, Robert Gabriel<sup>14</sup>, Slachevsky Andrea<sup>15-18</sup>, Stella Florindo<sup>19</sup>, Tribouillard Anaïs<sup>1,20,21</sup>, Trimarchi Pietro Davide<sup>22</sup>, Verhey Frans<sup>23</sup>, Yesavage Jerome<sup>8</sup>, Zeghari Radia<sup>1</sup>, Robert Philippe<sup>1,2,7</sup>

1. Université Côte d'Azur, CoBTeK lab, Nice, France
2. Association Innovation Alzheimer, Nice, France
3. School of Philosophy, Psychology and Language Sciences, University of Edinburgh, UK
4. Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, UK
5. Department of Psychiatry, Instituto de Investigación Sanitaria (imas12), Hospital Universitario 12 de Octubre & CIBERSAM, Madrid, Spain
6. INRIA, STARS team, Sophia Antipolis, France
7. Centre Hospitalier Universitaire (CHU) de Nice, CMRR, Nice, France
8. Department of Veterans Affairs, VA Palo Alto Health Care System, California, and Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, California.
9. Regional Resource Center of old age Psychiatry Corentin-Celton Hospital, Academic Hospital West Paris, Psychiatric department, AP-HP, Paris, France. Paris Descartes University, Sorbonne Paris Cité, Paris, France
10. Nuffield Department of Clinical Neurosciences (John Radcliffe Hospital, Oxford OX3 9DU) & Department of Experimental Psychology, University of Oxford, UK & Wellcome Centre for Integrative Neuroimaging, University of Oxford, UK.
11. Hopital Broca, Assistance Publique-Hôpitaux de Paris, Paris, France et Université Paris Descartes, Paris, France
12. Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK
13. Alzheimer Scotland Dementia Research Centre, University of Edinburgh, UK
14. EA4712 "Comportement et noyaux gris centraux", Université de Rennes1, France
15. Geroscience Center for Brain Health and Metabolism (GERO), Faculty of Medicine, University of Chile, Santiago, Chile
16. Neuropsychology and Clinical Neuroscience Laboratory (LANNEC), Physiopathology Department - ICBM, Neurociencia and East Neuroscience Departments, Faculty of Medicine, University of Chile
17. Memory and Neuropsychiatric Clinic (CMYN) Neurology Department, Hospital del Salvador and Faculty of Medicine, University of Chile, Santiago, Chile
18. Servicio de Neurología, Departamento de Medicina, Clínica Alemana-Universidad del Desarrollo, Santiago, Chile
19. Laboratório de Neurociências LIM27, Departamento e Instituto de Psiquiatria, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, SP, Brasil; UNESP – Universidade Estadual Paulista, Biosciences Institute, Campus of Rio Claro, SP, Brazil
20. ISTR, Institute of Rehabilitation Sciences and Techniques, University of Lyon 1, Lyon, France
21. Specialised Alzheimer Team, SSIAD Quimper, France
22. IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy

23. Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience (MHeNs), Alzheimer Center Limburg, Maastricht, The Netherlands

**Corresponding author:**

Valeria Manera, CoBTek lab - Université Côte d'Azur  
Institut Claude Pompidou  
10 rue Molière 06100 - Nice - France  
Valeria.manera@unice.fr

## Abstract

Apathy is a common neuropsychiatric syndrome observed across many neurocognitive and psychiatric disorders. Although there are currently no definitive standard therapies for the treatment of apathy, non-pharmacological treatment (NPT) is often considered to be at the forefront of clinical management. However, guidelines on how to select, prescribe and administer NPT in clinical practice are lacking. Furthermore, although new Information and Communication Technologies (ICT) are beginning to be employed in NPT, their role is still unclear. The objective of the present work is to provide recommendations for the use of NPT for apathy, and to discuss the role of ICT in this domain, based on opinions gathered from experts in the field. The expert panel included 20 researchers and healthcare professionals working on brain disorders and apathy. Following a standard Delphi methodology, experts answered questions via several rounds of web-surveys, and then discussed the results in a plenary meeting. The experts suggested that NPT are useful to consider as therapy for people presenting with different neurocognitive and psychiatric diseases at all stages, with evidence of apathy across domains. The presence of a therapist and/or a caregiver is important in delivering NPT effectively, but parts of the treatment may be performed by the patient alone. NPT can be delivered both in clinical settings and at home. However, while remote treatment delivery may be cost and time-effective, it should be considered with caution, and tailored based on the patient's cognitive and physical profile and living conditions.

**Implications for Practice and Research.** NPT should be tailored to deficits (e.g., cognitive, physical), clinical objectives (e.g. prevention, intervention) and preferences (e.g. personal, sensory) of each patient. ICT may help to improve treatment personalization, increase motivation, and aid remote treatment delivery. Further structured research (e.g., RCT) is needed to determine NPT efficacy.

**Keywords:** Apathy; motivation; complementary therapies; prescriptions, non-drug; ICT; brain disorders

## **Introduction**

In various brain disorders, apathy is consistently defined as a multidimensional syndrome characterized by a significant reduction in goal-directed activity<sup>1-5</sup>. Different apathy dimensions or subtypes include symptoms in relation to behavior (reduced level of activity, initiative), cognition (reduced interests, motivation for planning), emotions (emotional blunting, indifference, affective flattening) and social interaction (reduced social activities and engagement)<sup>3-5</sup>. Apathy is prevalent across many neurocognitive disorders (NCD, DSM-5<sup>6</sup>) and psychiatric disorders (PSY). It represents the most common behavioural and psychological symptom in people with Alzheimer's Disease (AD), and is often observed in Parkinson's disease (PD), vascular dementia, stroke, traumatic brain injury, amyotrophic lateral sclerosis/motor neurone disease (ALS/MND), frontotemporal dementia, progressive supranuclear palsy (PSP), small vessel disease, major depression and schizophrenia<sup>7</sup>.

Pharmacological therapies have demonstrated limited efficacy in the management of apathy associated with NCD and neuropsychiatric conditions. Methylphenidate has been observed as potentially beneficial in reducing levels of apathy in people with AD, and rivastigmine may be beneficial for people with PD, but these findings are associated with weak evidence<sup>8-9</sup>. Non-pharmacological treatment (NPT) - or *ecopsychosocial* interventions<sup>10</sup> - are often considered to be at the forefront of apathy management<sup>11</sup>. NPTs aim to address the cognitive, psychological, social, personal and relational functioning of the person. Usually these interventions use a “person-centered” rather than a “symptom-centered” approach, since they address not only the primary symptoms of a condition, but also the secondary experiences that arise as a consequence of the condition<sup>12</sup>. NPTs include a wide range of methods, such as group activities, therapeutic dialogs, meditation, and sensory, physical and physiological stimulation (Table 1). The scope of NPTs is broad and covers different dimensions such as cognition, motor skills, functional abilities, psycho-behavioral symptoms, social life and self-esteem. The general goals of these types of interventions are to strengthen cognitive, psycho-affective and social skills to reduce psycho-behavioral symptoms, to

preserve the patient's social activity, to restore confidence and self-esteem and to promote autonomy as well as quality of life<sup>13</sup>.

A variety of NPTs (symptom specific and symptom non-specific) have proven useful for the treatment of apathy. In people with Mild and Major NCD, for example, NPTs have been shown to be effective in improving apathy administered alone<sup>11</sup> or combined with drug therapy<sup>14,15</sup>. A summary of the NPTs employed to reduce apathy (as a direct or indirect target), and the clinical populations on which they have been employed is presented in Table 1 (see<sup>11,14,16</sup> for more exhaustive reviews).

[Table 1]

Information and Communication Technologies (ICT) have also started to be employed in NPTs to train cognitive and physical functions, promote communication, reduce loneliness and improve the emotional state in apathetic and non-apathetic patients. These include, Virtual Reality<sup>32</sup>, Serious Games (i.e., video-games designed to train cognitive and/or physical functions<sup>18,36</sup>), and social robots<sup>11</sup>. Remote NPT delivery through telemedicine interfaces is also starting to be explored for elderly people with cognitive impairment<sup>37</sup>.

Although most studies of NPTs have demonstrated promising results, the improvements in apathy do not seem long-lasting (from one week to several months, depending on the study)<sup>38</sup>, and results have been difficult to reproduce due to variability in the treatment delivery and conditions<sup>11</sup>. In most of the existing Randomized Controlled Trials (RCT), apathy was not the primary intervention target and the main endpoint. Similarly, apathy was rarely measured using multi-dimensional scales. The wide variability in sample size, diagnosis, apathy assessment, follow-up duration, and intervention conditions make it hard to provide strong conclusions on NPT efficacy in apathy management<sup>7</sup>. The field would benefit from more well-designed clinical studies (RCT) employing apathy as the main endpoint. These studies could focus on understanding which treatments are most effective for different pathologies, and in which conditions, as well as where, when, and how often

they should be implemented. The objective of the present work was to gather recommendations from experts in the field concerning the use of NPTs for apathy, and the role of ICT in delivering NPTs.

## **Methods**

The task force included 20 experts (researchers and healthcare professionals) in the domain of apathy in NCD and PSY. The experts were from 8 different countries (France, United Kingdom, USA, Italy, Brazil, Spain, Chile, the Netherlands). The experts' main professional backgrounds were Psychiatry (N=8), Psychology (N=8), Neurology (N=2), Speech Therapy (N=1) and ICT (N=1). All of them had more than five years of experience in the domain of apathy (9 participants with 5 to 10 years of experience, 5 participants with 10 to 20 years of experience, and 6 participants with more than 20 years of experience). Following a standard Delphi methodology<sup>39</sup> the recommendations were developed in a two-step process: web-surveys followed by a consensus meeting.

### ***Web-surveys***

The experts were asked to answer questions via a web-survey in three rounds (between November 2018 and March 2019) using Microsoft Forms. After each round, a facilitator (PR) provided a summary of the experts' responses, and encouraged the experts to analyze, comment and (eventually) revise their earlier responses considering the commentaries of other members of the panel. Questions in the three rounds included 13 rating questions (Supplementary Table 1): 9 (questions 1 to 9) focused on classical NPTs, 4 (questions 10 to 13) on the use of new ICT in NPT. For each question, participants rated their degree of agreement by employing a 5-point Likert scale (1=Not important/pertinent at all; 2=Not very important/pertinent; 3=Important/Pertinent; 4=Very important/pertinent; 5=Extremely important/pertinent). After each rating question, participants could provide comments. Round 1 also included the following open question: "Please report the 3 most important limitations and benefits of using ICT in NPT for apathy". The list of reported benefits and

limitations was employed as a starting point to perform a SWOT analysis (Strengths, Weaknesses, Opportunities, and Threats) of the use of ICT for NPTs. Several open questions were asked in rounds 2 and 3 to comment on the responses provided in rounds 1 and 2. After round 2, a first draft of the recommendations was circulated among the experts.

### ***Final consensus meeting***

The three web-surveys' results and the open discussion points were revised by the task force during a plenary meeting held on March 8, 2019 in Nice (France).

## **Results**

The results of the rating questions (median and interquartile range, IQR) are reported in Supplementary Table 1. The number of responses obtained for each question ranged from 14 to 16.

### **General questions**

*NPT for whom* (Q1). The experts reported that NPTs for apathy are 'extremely important' for patients with Major NCD (defined in the DSM-5 as a significant cognitive decline interfering in the independence of the individual with relation to everyday activities due to pathologies including AD, PD and other neurodegenerative disorders), and 'very important' for people with schizophrenia / psychotic disorders, depressive disorders, and Mild NCD (defined in the DSM-5 as a noticeable decrement in cognitive functioning that goes beyond normal changes seen in aging, with independence and autonomy is activities of daily living preserved thanks to compensatory strategies). Apathy NPTs were rated as 'important' for people with Post-Traumatic Stress Disorders, and subjective cognitive decline (SCD, characterized by cognitive complaints associated to unimpaired performance on cognitive tests). The difference in level of importance was reported mainly because apathy shows a higher prevalence in patients with severe impairments<sup>40,41</sup>. The experts also



considered NPTs to be important for targeting apathy in the context of limbic and paralimbic tumors, personality disorders, Traumatic Brain Injury, stroke, small vessel disease, and ASL/MND.

***NPT for what*** (Q2). Participants considered apathy NPTs to be ‘extremely important’ or ‘important’ for patients presenting symptoms in the different dimensions listed in the 2018 Diagnostic Criteria for Apathy, namely behavior/cognition, emotion and social interaction<sup>3</sup>. Apathy is consistently described as a multidimensional construct, and it is recognized that different apathy dimensions may be differently impaired in different pathologies<sup>5,41</sup> and have different neural substrates<sup>42</sup>. Different NPTs may be suitable to help those with impairments in different apathy dimensions. However, there is not enough evidence suggesting differential efficacy of NPTs for specific apathy dimensions, as studies typically employ global apathy measures only<sup>11</sup>. In addition, there is still no final consensus on the number and type of apathy dimensions, meaning that different apathy scales capture different apathy dimensions<sup>43-45</sup>. The experts acknowledged the need and importance for further research in order to converge in the understanding of the construct of apathy. Additionally, experts acknowledged the need to determine whether NPT treatments targeting specific apathy dimensions may also be useful to target conditions showing a partial overlap with apathy, such as anhedonia, depression and chronic fatigue<sup>7</sup>.

***NPT based on what***. When asked what factors are the most important for selecting the best NPT (Q3), the level of severity of the disease (cognitive and functional impairment) was rated as ‘extremely important’, while the age of the patient and the environment and lifestyle were rated as ‘very important’. Participants acknowledged that it is ‘extremely important’ to choose NPT based on the personal interests and sensory preferences (e.g., favorite colors, music, odors; Q4). This is in line with previous research suggesting that personalized interventions are a key aspect to improve or maintain treatment adherence and efficacy<sup>11</sup>. The most appropriate methods to collect patient’s needs and interests (Q5) were structured and semi-structured interviews, ICT and Serious Games (‘very appropriate’), while open questions were rated as between ‘appropriate’ and ‘very appropriate’. The most appropriate methods to collect patients’ *sensory* preferences (Q6) were observation by exposure,

semi-structured interviews, and ICT/serious games ('very appropriate'), while assessment performed by others (clinicians or caregivers) was rated between 'appropriate' and 'very appropriate', and self-evaluation as 'appropriate'. The experts highlighted the importance of developing standardized tests to collect patients' sensory preferences, which should be validated and compared to what is obtained in observation by exposure or observed in routine care.

Multisensory interventions, in which several senses are stimulated simultaneously, have showed promising results in reducing apathy<sup>11</sup>, however, which (and how many) senses should be stimulated is still debated<sup>46</sup>. Participants reported that in multi-sensory interventions it is 'very appropriate' to stimulate sight, hearing, smell and touch, and that stimulating taste is rated as between 'appropriate' and 'very appropriate' (Q7), mainly due to difficulties in materials available (e.g., the use of foods and drinks in a therapeutic setting).

***NPT with whom.*** In Q8 participants reported that it is 'very pertinent' to administer NPT in individual sessions, while it is 'pertinent' to administer them in group sessions. The preference for individual sessions was mainly explained by the need for achieving personalized objectives. Patients with different types and degrees of impairment, different deficits and different personal preferences should be stimulated in different ways. However, group sessions might be relevant to stimulate social interactions. The presence of a therapist (physical or virtual) was reported as a key element in designing NPT. Indeed, the interaction with the therapist can promote positive emotions and affect, which can be useful in facilitating patients' motivation and maintain engagement in the treatment. But it was acknowledged that the therapist would not necessarily have to be present continuously. For instance, through ICT, patients may also continue treatment sessions alone<sup>18</sup>.

***When.*** To decide if and when to prescribe or administer NPT for apathy (Q9), participants reported that it is 'extremely important' that the patient and/or caregivers consider apathy as a problem. The availability of NPT adapted to the patient's needs, the patient's willingness to adhere to the NPT and the stage of the disease were rated as 'very important'. It was acknowledged that the

decision of whether to propose NPT for apathy should be taken by clinicians in collaboration with patients and caregivers. Therefore, it is important to examine the mechanisms that lead to apathy, and not see apathy as a symptom that always requires treatment. For instance, apathy in people at the end of life may not be appropriate to target for therapeutic intervention.

## **Questions focused on ICT**

***ICT for NPT.*** Participants reported that ICT is ‘very appropriate’ for apathy NPT (Q10). All participants (N=15) agreed that there is a good benefit/risk ratio in using ICT for apathy NPT, and 13 participants out of 15 agreed that ICT can be used to continue or maintain adherence to the intervention without the presence of the therapist. As detailed below, the experts highlighted the importance of considering the degree of patients’ cognitive and functional impairment in order to evaluate the usability of ICT-based NPT. The presence of a caregiver was considered as critical for people with advanced impairment at the cognitive and functional level.

***Telemedicine platforms.*** Participants reported that it is ‘very appropriate’ to deliver NPT remotely by employing ICTs, such as tele-medicine platforms and Virtual Reality environments (Q11) for individual sessions, while it is ‘adapted’ for group sessions. Video-conference, audio-conference, Virtual Reality (VR) immersive environments and the use of a virtual coach were all rated as ‘very appropriate’ to deliver NPT treatments remotely (Q12), with the lowest scores (‘appropriate’) assigned to audio-conference platforms. Based on ongoing clinical trials, the experts suggested that the selected platform should allow monitoring online of a patient’s reactions to treatment, as well as to verify that the patient is following the treatment correctly<sup>37</sup>. The decision of which platform to employ should be taken based on which elements are important to capture. For instance, in physical training it is important that patient and therapist can see each other. However, a

VR interface in which patient and therapist can share a screen may be more adapted for cognitive training sessions.

Concerning the delivery of NPTs remotely (Q13), the presence of a caregiver was rated as ‘very important’, in order to guarantee the system usability, safety and efficacy. The level of cognitive and functional impairment of the patient and his/her familiarity with ICT were rated between ‘important’ and ‘very important’ (learning to employ ICT may be part of the patients’ training, depending on their level of cognitive impairment). Where the patient lives (e.g., distance from clinical facilities) was rated as ‘important’, and home-based and/or long-term frequent treatments delivered remotely may be more convenient.

## **SWOT analysis of ICT for NPT**

A SWOT analysis (Strengths, Weaknesses, Opportunities, and Threats) of the use of ICT for NPTs is reported in Table 2.

[Table 2]

**Strengths.** ICT can help in standardizing the treatment conditions (e.g. reproducibility, contents and automatic follow-up), and collecting non-invasive objective, measurable and longitudinal data on participants’ adherence to treatment and their performance. Also, ICT is useful to tailor and personalize the intervention. Compared to classical treatments, ICT interventions are easier to adapt to the personal interests (e.g., serious games to train executive functions based on a cooking plot vs a naval battle plot), sensory preferences (e.g., background color of ICT interface), the level of impairment (e.g., through algorithms that adapt the game difficulty online, in what has been defined closed-loop cognition<sup>47</sup>), and patient’s equipment (e.g. tablets, smartphones or VR headsets). Furthermore, ICT can provide more immersive, stimulating, and varied treatments with the potential to result in higher engagement and positive emotions. Finally, ICT can provide affordable and easy to use options, that can also be potentially used remotely.

**Weaknesses.** Some ICT-interfaces are not easy to install and use, especially for older adults, Relatedly, older adults may have a negative perception of ICT, as well as negative feelings engendered through not being able to use ICT. Furthermore, social interaction may be reduced by using NPT remotely. The presence of a therapist (and/or a caregiver) is a pre-requisite to mediate adherence to treatment, especially for people with more severe cognitive and functional impairment, and anosognosia. Also, newly released products can have high costs. In addition, not all high-tech interfaces are appropriate for people with cognitive impairment, or for specific cultural backgrounds, and may not embed challenges that make the training engaging. However, these aspects can be improved by designing interfaces tailored to specific categories of patients and deficits<sup>36</sup>. Finally, similar to classical NPT, there is a risk of accidents with remote training (e.g., risk of falls for physical activity trainings), and potentially a risk of addictive or habitual behavior, specifically linked to the use of video-games.

**Opportunities.** ICT is becoming increasingly affordable and easier to use. In parallel, its adoption is dramatically increasing (ESA, 2017). These trends represent opportunities for giving wider accessibility to NPT for people with apathy. Through delivering ICT-based NPT remotely, this would allow people living rurally, far from clinical facilities and/or with mobility problems, and eventually people living in middle- and low-income countries with limited access to neuropsychiatric centers, to get easier access to care. Also, ICT may help to deliver NPT at a large scale, and facilitate trainings for therapists, resulting in more standardized treatments.

**Threats.** ICT-based NPT (e.g., serious games, VR) often requires a long, expensive technical development and can be difficult to modify once it is released. Also, there is currently insufficient consistent evidence regarding the effectiveness, risk and impact, as well as cross-cultural validation of both classical and ICT-based NPT. Due to these limitations, ICT-based NPTs often result in poor acceptance in the medical community<sup>48</sup>.

## **Discussion**

NPTs are currently employed as frontline treatments for apathy in people with different brain disorders<sup>11</sup> and previously reported NPTs have shown initial promising results in improving apathy (Table 1). However, the field urgently need more methodologically-sound studies (RCT) to assess the efficacy of specific NPTs, and to standardize treatment materials and conditions. Here we gathered recommendations from experts on how to progress the field further. Converging with previous studies, our results suggested several important implications for clinical practice and research.

***Early detection of apathy.*** In NCD apathy can appear at the early stages of the disease progression<sup>49</sup>. Apathy is recognized as a multidimensional construct; reduction in goal-directed activities can be found in the domains of behavior, cognition, emotions and social interaction<sup>3</sup>. To implement early interventions, it is necessary to assess apathy early in the disease progression. The experts suggested that more collaborative research would be needed for further convergence of understanding of the construct of apathy. The 2018 Diagnostic Criteria for Apathy (DCA)<sup>3</sup> may be particularly useful in this context, as they are a) transdiagnostic, making it possible to compare apathy in different populations, and b) multidimensional, providing a method to obtain a composite apathy profile. Furthermore, c) they form the basis for potential clinical scales and ICT-based instruments to detect each apathy dimensions. Employing the 2018 DCA in the clinical practice may contribute to increasing comparability of results across clinical centers. Crucially, the experts recommended that future studies employ multidimensional apathy assessment (e.g., Apathy Motivation Index<sup>43</sup>; Dimensional Apathy Scale<sup>44,45</sup>) to better understand the differential effects of different NPT. Finally, impairments in apathy dimensions should also be reported for patients not fulfilling the DCA. Indeed, isolated symptoms such as lack of interest and/or social interaction are also found in a significant proportion of individuals without clinical apathy<sup>41</sup>. The presence of some isolated symptoms – for instance lack of interest - may be due to a partial overlap between apathy and other clinical conditions, such as depression<sup>4</sup>. However, symptoms may also appear in isolation and independently of these

conditions. Knowing which isolated symptoms preceded – for months or years – an apathy diagnosis would help to better understand how apathy develops and unfolds over time.

**Early intervention.** In clinical settings, symptom-specific and non-specific NPTs for apathy are more commonly employed in people with well-established pathological conditions<sup>11</sup>. However, in NCD apathy can appear at the early stages of the disease progression, even in people with SCD. The presence of apathy has been associated with a faster cognitive and functional decline<sup>50</sup>, representing a risk factor for the conversion from MCI to AD<sup>51</sup>. Critically, preliminary evidence suggests that interventions targeting apathy in people with MCI (e.g. with repetitive transcranial magnetic stimulation, rTMS) may be effective in improving the global cognitive functioning<sup>33</sup>. Thus, putting in place early treatment options for MCI or even SCD might offer new opportunities for altering the trajectory of Alzheimer’s Disease dementia. Apathy has also been observed as prevalent in early stages of other neurodegenerative conditions, such as PD<sup>52</sup> and ALS/MND<sup>53</sup>. Therefore, an important area for future investigate is the development of NPTs for apathy at the early stages of disease processes.

**Personalized therapy.** Generic approaches to activities may fail to produce positive changes in many patients: the more the treatment is tailored to the person, the higher the probability that the treatment is effective<sup>54</sup>. At a clinical level, “tailor-made” approaches are required, including designing specific meaningful activities depending on individuals’ interests, needs, abilities and capacities<sup>55</sup>, and in line with their perceived self and identity<sup>56</sup>. Sensory preferences (e.g. what the person likes to touch, smell, eat, his/her favorite colors and music) of the person are also important aspects to consider. Further, collecting personal interests, needs, preferences and identities are not trivial when dealing with people with neurocognitive and neuropsychiatric disorders. At a research level, it is important to develop instruments that would be able to capture these aforementioned preference dimensions in a standardized way. Semi-structured interviews and serious games represent such promising instruments.

***The role of ICT.*** In line with previous recommendations<sup>48,57</sup>, the experts suggested that ICT may play an important role in NPT for apathy. The use of ICT in NPT for apathy is still in an early phase of development, characterized by encouraging initial research results<sup>48</sup>. The many listed strengths - including improving treatment standardization, non-invasive and continuous monitoring of patients' apathy, and remote treatment delivery - provide a justification for further development of ICT as NPT for apathy. However, some weaknesses were noted (in particular concerning the difficulty that older patients experience with using ICT alone), as well as some threats, none of which were deemed to be major. At the practical level, it would be important to develop easy-to-use, affordable ICT solutions for clinicians that can be implemented in everyday practice, and potentially be employed remotely, with the help of a caregiver. At a research level, it is important to collect methodologically-sound data to test and evolve usability, usefulness and efficacy of ICT-based NPTs targeting people with brain disorders.

In summary, through expert consensus, improving early detection and early treatment may be valuable in characterizing and managing apathy as a syndrome in brain disorders. Furthermore, personalized NPT approaches for apathy may provide stronger evidence of NPT efficacy, which would result in clearer guidelines for NPT prescription or administration and delivery. ICT may play a role in facilitating NPT delivery, standardization and assessment, provide a potential future avenue for development methods of management, treatment and interventions for apathy.

### **Acknowledgements**

This work was supported by the Association IA, the JL Noisiez Fondation, and by the French government, through the UCA-JEDI “Investments in the Future” project managed by the National Research Agency (ANR) with reference number ANR-15-IDEX-01. The recommendations were drafted in the context of the MNC3 program. RR was supported by Motor Neurone Disease Association and Motor Neurone Disease Scotland. AS was supported by FONDAP Program Grant 15150012.



Table 1: Different types of NPT used in different populations with apathy as a direct or indirect target.

Approach	Description of the intervention	Mainly used in
Art Therapy	Form of psychotherapy that uses art media as its primary mode of communication to enable a patient to change and grow on a personal level through the use of art materials in a safe and facilitating environment.	Mild and Major NCD (including AD, all stages) <sup>11</sup>
Cognitive interventions	Cognitive stimulation, training or rehabilitation designed to solicit one or more cognitive functions such as attention, memory, language, orientation to maintain, improve or compensate for them. This includes both classical and computerized interventions (e.g., serious-games)	Mild and Major NCD <sup>17,18</sup> ; PSP <sup>19</sup> , Schizophrenia <sup>20</sup> ; PD <sup>21</sup> ; Acute Stroke <sup>22</sup>
Animal assisted Therapy (AAT)	Based on patient-animal-therapist interaction, AAT is an individual or group intervention carried out in care settings by a professional to improve mental, cognitive, physical, social and/or emotional functioning of patient.	AD (moderate stage) <sup>23</sup>
Motivational Interviewing	Collaborative client-centered approach designed to enhance internal motivation for behavior change through the reduction of patient ambivalence feelings. It is based on several social and behavioral principals such as empathy, decisional balance and reduction of resistance to change.	TBI <sup>24</sup>
Physiotherapy	Science-based profession aimed to help people affected by injury, illness or disability through movement and exercise, manual therapy, education and advice.	Acute Stroke <sup>25</sup> , PD <sup>26</sup>
Multi-sensory Stimulation/Snoezelen	Person-centered care approach using i.e lights, aroma therapy, music/sounds, tactile objects, and/or screen	Major NCD <sup>11</sup>

	projectors in an immersive environment to actively stimulate one or more of the different senses (vision, audition, tact, olfaction and taste).	
Music therapy	Clinical active or receptive interventions using music, its instruments and properties in individual or group settings to optimize people's quality of life and improve their different functions (physical, social, communicative, emotional, intellectual).	Mild and Major NCD (including AD, all stages) <sup>11</sup>
Occupational therapy (OT) interventions	In a client-centered care approach, OT accompanies people encountering disability situations in order to improve, maintain or compensate their participation in activities of daily living. With regards to Apathy, OT can provide to the patient and his/her caregiver with more engaging and personalized strategies and a program of tailored activities, customized to previous and current interests, residual functional capacities and patient's level of cognitive decline.	Mild and Major NCD (including AD, all stages) <sup>11,27,28</sup> ; PD <sup>29</sup>
Physical activity	Physical exercise can have positive effects on both physical function and mental health. Physical exercise can aim to improve muscle strengths (lower and upper limbs), balance, mobility, and to reduce stress. Examples of activities include: strengthening and balance exercises, cycling, swimming, yoga and Pilates.	PD <sup>26</sup> ; Major NCD and Stroke <sup>30</sup>
Reminiscence	Therapy based on the evocation and discussion about personal past activities, events and life experiences, in individual or group settings, using a variety of supporting meaningful materials.	Major NCD (including AD, all stages) <sup>11</sup>

Assistive social robots	Therapeutic or recreational interventions that use social robots (animal-like, human-like) as a support to promote communication, reduce loneliness and improve the emotional state of the user.	Major NCD <sup>11</sup>
Staff or caregiver education program	The learning of behavioural strategies to manage apathy in care settings or in-home care and reduce its negative consequences.	Neurological conditions (AD, PD, etc.) <sup>31</sup> ; Mild NCD <sup>27</sup> ; PSP <sup>19</sup>
Virtual Reality (VR)	VR is an ICT used in healthcare setting to help diagnosis or to treat cognitive, psychological or physical pathologies. Its strengths consist of ecological validity, which can facilitate the transfer of VR learning to the real world, its ludic aspect and the possibility of personalization of the immersive environment.	Mild NCD <sup>32</sup>
Repetitive Transcranial Magnetic Stimulation (rTMS)	Non-invasive treatment consisting of magnetic stimulation sessions using a figure-of-eight-shaped coil applied on a target cranial surface in order to increase cortical activity and modulate cerebral networks.	Mild NCD <sup>33</sup> ; PD <sup>34</sup> ; Chronic stroke <sup>35</sup>

NCD = Neurocognitive Disorder; PD = Parkinson's Disease; TBI = Traumatic Brain Injury; AD = Alzheimer's Disease; PSP = Progressive Supranuclear

Palsy

Table 2. Summary of a SWOT analysis of using ICT for apathy NPT

Strengths	Weaknesses
<ul style="list-style-type: none"> <li>- Can facilitate reproducibility and standardization (contents and automatic follow-up)</li> <li>- Increased ecological validity, can put a patient in a 'reality-like' setting but more controlled</li> <li>- Possibility to record patient activity and adherence to treatment automatically, longitudinally and remotely, on-line or off-line;</li> <li>- Possibility to record and analyze several "indirect" data (voice, movements, etc.)</li> <li>- Adaptation to the user (e.g., impairment type and level, personal interest)</li> <li>- Increased variety of activities, and easy content adaptation (themes, ergonomics) to increase engagement</li> <li>- Flexibility of use (multiple supports: tablet, smartphone, computer, tv screen...)</li> <li>- Can increase motivation, curiosity, immersion and positive emotions</li> <li>- Can stimulate attention and other cognitive processes in a controlled environment</li> <li>- Useful for long training sessions, allowing to extend patient activity at home</li> <li>- Cost-effectiveness (e.g., tablets, actigraphy)</li> <li>- Easy setup (for some devices)</li> <li>- No requirement of a therapist to be present all the time</li> <li>- Can be used for group stimulations</li> </ul>	<ul style="list-style-type: none"> <li>- Time-consuming setup (for some devices)</li> <li>- ICT interfaces and software difficult to use</li> <li>- Poor understanding (and fear of not understanding) of the technology</li> <li>- Need of patients' and staff's training</li> <li>- Need of caregivers' implication for people with Major Neurocognitive Disorder</li> <li>- Expensive equipment (e.g., VR headsets)</li> <li>- Absence of human contact (risk of reducing the opportunities of social interaction)</li> <li>- Possibility of poor engagement/interest</li> <li>- Games not embedding cognitive challenges</li> <li>- Games potentially not appropriate for participant's cognitive profile and culture</li> <li>- Lack of generalization to patient's environment (activities far from reality)</li> <li>- Side effects such as hallucinations, loss of sense of reality (e.g. for Virtual Reality)</li> <li>- Risk of accidents (e.g., risk of falls, increased sleep disturbances)</li> <li>- Risk of addiction</li> <li>- Low standardization</li> </ul>
Opportunities	Threats
<ul style="list-style-type: none"> <li>- Emerging advances in technology</li> <li>- Good accessibility for users, also remotely (at home or in remote clinical facilities)</li> <li>- Increasing number of seniors commonly using ICT</li> <li>- Could help reducing barriers in access to care in middle- and low-income countries with limited access to neuropsychiatric centers</li> <li>- Usable at large scale</li> <li>- Can be used trans-diagnostically</li> <li>- Can facilitate training sessions for therapists</li> </ul>	<ul style="list-style-type: none"> <li>- Long and expensive technical development, difficult to modify</li> <li>- Low experience in ICT by users</li> <li>- Cognitive/behavioral fundamentals of the classical therapies are not fully reproduced</li> <li>- Not enough research evidence towards effectiveness, risk and impact.</li> <li>- Absence of cross-cultural validation of NTP, and inappropriate adoption in non-adapted cultural domains.</li> <li>- Unrealistic belief that ICT can remedy everything</li> <li>- Digital divide</li> <li>- Poor acceptance in the medical community</li> </ul>

## References

1. Marin R. Apathy: a neuropsychiatric syndrome. *The Journal of Neuropsychiatry and Clinical Neurosciences*. 1991;3(3):243-254.
2. Robert P, Onyike C, Leentjens A, Dujardin K, Aalten P, Starkstein S et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. *European Psychiatry*. 2009;24(2):98-104.
3. Robert P, Lanctôt K, Agüera-Ortiz L, Aalten P, Bremond F, Defrancesco M, Hanon C, [...], Manera V. Revision of the Diagnostic Criteria for Apathy in Brain Disorders: The 2018 International Consensus Group. *European Psychiatry*. 2018; 54:71-76.
4. Levy R., Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. *Cereb Cortex*. 2006;16:916–928
5. Radakovic R., Abrahams S. (2018) Multidimensional apathy: evidence from neurodegenerative disease. *Current Opinion in Behavioral Sciences* 2018; 22: 42-49.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). (2013). Arlington, VA: Author
7. Husain M., Roiser J.P. (2018). Neuroscience of apathy and anhedonia: a transdiagnostic approach. *Nature Reviews Neuroscience*, 19, 470–484.
8. Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL. Pharmacological interventions for apathy in Alzheimer's disease. *Cochrane Database of Systematic Reviews* 2018, Issue 5. DOI: 10.1002/14651858.CD012197.pub2.
9. Seppi, K. , Ray Chaudhuri, K. , Coelho, M. , Fox, S. H., Katzenschlager, R. , Perez Lloret, S. Weintraub, D. , Sampaio, C.,(2019), Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. *Mov Disord.*, 34: 180-198. doi:[10.1002/mds.27602](https://doi.org/10.1002/mds.27602).
10. Zeisel, J, Reisberg B, Whitehouse P, Woods R, Verheul A. Ecopsychosocial Interventions in Cognitive Decline and Dementia: A New Terminology and a New Paradigm. *Am J Alzheimers Dis Other Dement*. 2016 Sep;31(6):502-7. doi: 10.1177/1533317516650806.
11. Theleritis, C., Siarkos, K., Politis, A. A., Katirtzoglou, E., & Politis, A. (2018). A systematic review of non-pharmacological treatments for apathy in dementia. *International Journal of Geriatric Psychiatry*, 33(2), e177–e192. <https://doi.org/10.1002/gps.4783>
12. Turton, W. (2014) An introduction to psychosocial interventions. In Walker, S. (ed.). *Psychosocial interventions in mental health nursing*. (4-21). SAGE. Learning Matters.
13. Zuchella C, Sinforiani E, Tamburin S, Federico A, Mantovani E, Bernini S, Casale R, Bartolo M. The Multidisciplinary Approach to Alzheimer's Disease and Dementia. A

- Narrative Review of Non-Pharmacological Treatment. *Front. Neurol.*, 13 December 2018.  
<https://doi.org/10.3389/fneur.2018.01058>
14. De Oliveira AM, Radanovic M, de Mello PCH, Buchain PC, Vizzotto ADB, Celestino DL, et al. Nonpharmacological Interventions to Reduce Behavioral and Psychological Symptoms of Dementia: A Systematic Review. *BioMed Res Int* [Internet]. 2015 [cited 2018 Sep 23];2015. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676992/>
  15. Scales K, Zimmerman S, Miller SJ. Evidence-Based Nonpharmacological Practices to Address Behavioral and Psychological Symptoms of Dementia. *The Gerontologist* [Internet]. 2018 Jan 18 [cited 2018 Aug 15];58(suppl\_1):S88–102. Available from: [https://academic.oup.com/gerontologist/article/58/suppl\\_1/S88/4816740](https://academic.oup.com/gerontologist/article/58/suppl_1/S88/4816740)
  16. Olley R, Morales A. Systematic review of evidence underpinning non-pharmacological therapies in dementia. *Aust Health Rev* [Internet]. 2018 [cited 2018 Sep 23];42(4):361. Available from: <http://www.publish.csiro.au/?paper=AH16212>
  17. Buettner, L. L., Fitzsimmons, S., Atav, S., & Sink, K. (2011). Cognitive Stimulation for Apathy in Probable Early-Stage Alzheimer's. *Journal of Aging Research*.  
<https://doi.org/10.4061/2011/480890>
  18. Manera V, Petit P-D, Derreumaux A, Orvieto I, Romagnoli M, Lyttle G, David R and Robert PH (2015) 'Kitchen and cooking,' a serious game for mild cognitive impairment and Alzheimer's disease: a pilot study. *Front. Aging Neurosci.* 7:24. doi:  
10.3389/fnagi.2015.00024
  19. Rittman, T., Coyle-Gilchrist, I. T., & Rowe, J. B. (2016). Managing cognition in progressive supranuclear palsy. *Neurodegenerative Disease Management*, 6(6), 499–508.  
<https://doi.org/10.2217/nmt-2016-0027>
  20. Raffard, S., Gutierrez, L.-A., Yazbek, H., Larue, A., Boulenger, J.-P., Lançon, C., ... Capdevielle, D. (2016). Working Memory Deficit as a Risk Factor for Severe Apathy in Schizophrenia: A 1-Year Longitudinal Study. *Schizophrenia Bulletin*, 42(3), 642–651.  
<https://doi.org/10.1093/schbul/sbw002>
  21. Daniele, A., & Panza, F. (2018). Can a cognitive rehabilitation program in early stages of Parkinson's disease improve cognition, apathy and brain functional connectivity for up to 18 months? *European Journal of Neurology*, 25(2), 203–204.  
<https://doi.org/10.1111/ene.13542>
  22. Mikami, K., Jorge, R. E., Moser, D. J., Arndt, S., Jang, M., Solodkin, A., ... Robinson, R. G. (2013). Prevention of Poststroke Apathy Using Escitalopram or Problem-Solving Therapy. *The American Journal of Geriatric Psychiatry*, 21(9), 855–862.  
<https://doi.org/10.1016/j.jagp.2012.07.003>

23. Garzon, E., & Sillou, J.-M. (2014). Animal assisted therapy and Alzheimer disease: Improving on the apathy of patients in nursing home. *La Revue de Gériatrie*, 39(7), 429–438. Retrieved from <http://www.revuedegeriatrie.fr/index.php>
24. Lane-Brown, A., & Tate, R. (2010). Evaluation of an Intervention for Apathy After Traumatic Brain Injury: A Multiple-Baseline, Single-Case Experimental Design. *JOURNAL OF HEAD TRAUMA REHABILITATION*, 11.
25. Chen, L., Xiong, S., Liu, Y., Lin, M., Zhu, L., Zhong, R., ... Shang, X. (2019). Comparison of Motor Relearning Program versus Bobath Approach for Prevention of Poststroke Apathy: A Randomized Controlled Trial. *Journal of Stroke and Cerebrovascular Diseases*, 28(3), 655–664. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.11.011>
26. Subramanian, I. (2017). Complementary and Alternative Medicine and Exercise in Nonmotor Symptoms of Parkinson's Disease. In *International Review of Neurobiology* (Vol. 134, pp. 1163–1188). <https://doi.org/10.1016/bs.irn.2017.05.037>
27. Adam, S., De Linden, M. V., Juillerat, A.-C., & Salmon, E. (2000). The cognitive management of daily life activities in patients with mild to moderate Alzheimer's disease in a day care centre: A case report. *Neuropsychological Rehabilitation*, 10(5), 485–509. <https://doi.org/10.1080/09602010050143568>
28. Goris, E. D., Ansel, K. N., & Schutte, D. L. (2016). Quantitative systematic review of the effects of non-pharmacological interventions on reducing apathy in persons with dementia. *Journal of Advanced Nursing*, 72(11), 2612–2628. <https://doi.org/10.1111/jan.13026>
29. Leroi, I., David, R., & Robert, P. H. (2012). Apathy in Parkinson's Disease. *Psychiatry of Parkinson's Disease*, 27, 27–40. <https://doi.org/10.1159/000331524>
30. Telenius, E. W., Engedal, K., & Bergland, A. (2015). Effect of a High-Intensity Exercise Program on Physical Function and Mental Health in Nursing Home Residents with Dementia: An Assessor Blinded Randomized Controlled Trial. *PLOS ONE*, 10(5), e0126102. <https://doi.org/10.1371/journal.pone.0126102>
31. Braine, M. E. (2014). Apathy a common feature in many neurological conditions: care and management. *Australian Journal of Neuroscience*, 24(2), 12–22. Retrieved from <http://usir.salford.ac.uk/33435/>
32. Manera V, Chapoulie E, Bourgeois J, Guerchouche R, David R, Ondrej J, et al. (2016) A Feasibility Study with Image-Based Rendered Virtual Reality in Patients with Mild Cognitive Impairment and Dementia. *PLoS ONE* 11(3): e0151487. <https://doi.org/10.1371/journal.pone.0151487>
33. Padala, P. R., Padala, K. P., Lensing, S. Y., Jackson, A. N., Hunter, C. R., Parkes, C. M., ... Sullivan, D. H. (2018). Repetitive transcranial magnetic stimulation for apathy in mild

- cognitive impairment: A double-blind, randomized, sham-controlled, cross-over pilot study. *Psychiatry Research*, 261, 312–318. <https://doi.org/10.1016/j.psychres.2017.12.063>
34. Oguro, H., & Nakagawa, T. (2014). Randomized Trial of Repetitive Transcranial Magnetic Stimulation for Apathy and Depression in Parkinson's Disease. *Journal of Neurology & Neurophysiology*, 05(06). <https://doi.org/10.4172/2155-9562.1000242>
  35. Sasaki, N., Hara, T., Yamada, N., Niimi, M., Kakuda, W., & Abo, M. (2017). The Efficacy of High-Frequency Repetitive Transcranial Magnetic Stimulation for Improving Apathy in Chronic Stroke Patients. *European Neurology*, 78(1–2), 28–32. <https://doi.org/10.1159/000477440>
  36. Ben-Sadoun G, Manera V, Alvarez J, Sacco G and Robert P (2018); Recommendations for the Design of Serious Games in Neurodegenerative Diseases. *Front. Aging Neurosci.* 10:13. doi: 10.3389/fnagi.2018.00013
  37. Trimarchi, P. D., Locatelli, P., Cirilli, F., Tomasini, E., Moreno, P. A., & Pérez-Rodríguez, R. (2018). Elderly patients with cognitive impairment: Application of a new service and organizational model supported by digital solutions. *E-HEALTH 2018 ICT, SOCIETY AND HUMAN BEINGS 2018*, 12.
  38. Massimo L, Kales HC, Kolanowski A. State of the Science: Apathy As a Model for Investigating Behavioral and Psychological Symptoms in Dementia. *J Am Geriatr Soc* [Internet]. 2018 Apr [cited 2018 Sep 25];66(S1):S4–12.
  39. Linstone HA, Turoff M. (1975). *The Delphi Method: Techniques and Applications*. Reading, MA: Addison-Wesley
  40. Mulin E, Leone E, Dujardin K, Delliaux M, Leentjens A, Nobili F et al. Diagnostic criteria for apathy in clinical practice. *International Journal of Geriatric Psychiatry*. 2011;26(2):158-165.
  41. Manera V., Fabre R., Stella F, Loureiro JC., Agüera-Ortiz L, López-Álvarez J, Hanon C, Hoertel H, Aalten P, Ramakers I, Zeghari R, Robert P. (2019). A survey on the prevalence of apathy in elderly people referred to specialized memory centers has just been published in *International Journal of Geriatric Psychiatry*, in press
  42. Agüera-Ortiz L, Hernandez-Tamames JA, Martinez-Martin P, Cruz-Orduña I, Pajares G, López-Alvarez J, Osorio RS, Sanz M, Olazarán J. Structural correlates of apathy in Alzheimer's disease: a multimodal MRI study. *Int J Geriatr Psychiatry*. 2017; 32(8):922-930.
  43. Ang Y, Lockwood P, Apps M, Muhammed K, Husain M. Distinct Subtypes of Apathy Revealed by the Apathy Motivation Index. *PLOS ONE*. 2017;12(1):e0169938.



44. Radakovic R., Abrahams S. (2014). Developing a new apathy measurement scale: Dimensional Apathy Scale. *Psychiatry Research*, 219(3):658-663.
45. Radakovic, R., Stephenson, L., Colville, S., Swingler, R., Chandran, S., & Abrahams, S. (2016). Multidimensional apathy in ALS: validation of the Dimensional Apathy Scale. *Journal of Neurology, Neurosurgery, and Psychiatry*, 87(6), 663-669.
46. Banks SJ, Ng V., Jones-Gotman M. Does good + good = better? A pilot study on the effect of combining hedonically valenced smells and images. *Neuroscience Letters* 2012; 514(1)1-76.
47. Mishra J, & Gazzaley A. (2015). Closed-loop cognition: the next frontier arrives. *Trends Cogn Sci*. 2015 May;19(5):242-3. doi: 10.1016/j.tics.2015.03.008
48. Robert, P.H., König, A., Amieva, H., Andrieu, S., Bremond, F., Bullock, R., et al. (2014). Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailty. *Front. Aging Neurosci*. 6:54. doi:10.3389/fnagi.2014.00054
49. van Dalen J.W., van Wanrooij L.L., Moll van Charante E.P., Brayne C., van Gool W.A, Richard E. (2018). Association of Apathy With Risk of Incident DementiaA Systematic Review and Meta-analysis. *JAMA Psychiatry*, 75(10):1012–1021
50. Starkstein S., Jorge R., Misrahi R., Robinson R. (2006). A prospective longitudinal study of apathy in Alzheimer's disease. *Journal of Neurology, Neurosurgery & Psychiatry*, 77(1):8-11.
51. Ruthirakuhan M, Herrmann N, Vieira D, Gallagher D, Lanctot KL. The Roles of Apathy and Depression in Predicting Alzheimer Disease: A Longitudinal Analysis in Older Adults With Mild Cognitive Impairment. *Am J Geriatr Psychiatry*. 2019
52. Pedersen KF, Alves G, Brønnick K, Aarsland D, Tysnes OB, Larsen JP (2010). Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. *J Neurol*. 257(2):217-23. doi: 10.1007/s00415-009-5297-x
53. Crockford, C., Newton, J., Lonergan, K., Chiwera, T., Booth, T., Chandran, S., ... & Pender, N. (2018). ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. *Neurology*, 91(15), e1370-e1380.
54. Lanctot KL, Aguera-Ortiz L, Brodaty H, Francis PT, Geda YE, Ismail Z, et al. Apathy associated with neurocognitive disorders: recent progress and future directions. *Alzheimers Dement* 2017; 13: 84–100.
55. Starkstein S., Hayhow B. (2019). Apathy in Dementia: Time to StandUp. *The American Journal of Geriatric Psychiatry*, Volume 27, Issue 4, Pages 406–407.
56. Cohen-Mansfield J., Dakheel-Ali M., Marx MS. (2009). Engagement in persons with dementia: the concept and its measurement. *Am J Geriatr Psychiatry*, 17(4): 299–307. doi:

10.1097/JGP.0b013e31818f3a52

57. Manera, V., Ben-Sadoun, G., Aalbers, T., Agopyan, H., Askenazy, F., Benoit, M., Bensamoun, D., Bourgeois, J., Bredin, J., Bremond, F., Crispim-Junior, C., David, R., De Schutter, B., Ettore, E., Fairchild, J., Foulon, P., Gazzaley, A., Gros, A., Hun, S., Knoefel, F., Olde Rikkert, M., Phan Tran, M.K., Politis, A., Rigaud, A.S., Sacco, G., Serret, S., Thümmel, S., Welter, M.L., Robert, P. (2017). Recommendations for the Use of Serious Games in Neurodegenerative Disorders: 2016 Delphi Panel. *Frontiers in Psychology*, 8, 1243. doi: 10.3389/fpsyg.2017.012